logo

For the Inventor, By the Inventor

Tochigi, Japan

Muneki Nagao

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:

goldMedal5 out of 185 
 
Kyorin Pharmaceutical Co., Ltd.
 patents

Years Active: 2013-2019

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents
1. RE47785 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal (2019-12-30),
2. 9328089 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-YL}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal (2016-05-03),
3. 9108915 - Method for producing 3,4-disubstituted pyrrolidine derivative (2015-08-18),
4. 9090587 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluorodethyl)-acid crystal (2015-07-28),
5. 8501965 - Method for producing 3-substituted-4-fluoropyrrolidine derivative (2013-08-06),

Title: Muneki Nagao - Innovator in Pharmaceutical Research

Introduction

Muneki Nagao is an inventor based in Shiraoka-shi, Japan. He is known for his contributions to pharmaceutical research, particularly in the area of MRGPRX2 antagonists. Although he currently holds no granted patents, his work is significant in the field of medicinal chemistry.

Latest Patent Applications

Muneki Nagao's latest patent applications include innovative compounds aimed at treating MRGPRX2-mediated diseases or disorders. The applications detail pharmaceutical compositions that comprise these compounds, which are represented by a specific structural formula. These compositions are designed to provide therapeutic benefits for conditions associated with MRGPRX2.

Conclusion

Muneki Nagao's research and patent applications reflect his commitment to advancing pharmaceutical science. His work on MRGPRX2 antagonists holds promise for future medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…